ABSTRACT:
E.coli was reported as an uro-pathogen which is difficult to treat because of its multidrug resistance as well as its growth in biofilms. This study was designed to study resistance pattern, biofilm formation ability among uropathogenic E.coli, and to evaluate the action of Egyptian honey types as an antibacterial agent. Strains were collected, antibiotic susceptibility testing and extended-spectrum beta-lactamase (ESBL) detection were assessed. Biofilm formation ability was detected by the TCP method. The activity of Egyptian honey types (citrus, camphor, marjoram, and black seed honey) was tested by using agar well diffusion and micro-broth dilution techniques. 17 uropathogenic E. coli strains were collected, at which high resistance rates toward ampicillin, cephalosporins (ceftazidime/ cefotaxime) ranging from 77% to 100%. Imipenem was the most active antibiotic (94%). 64.7% were ESBL producers while only 35.3% were non-ESBL producers. 12 isolates (70.6%) were found to be biofilm formers at which 3 (17.7%) of them were categorized as moderate biofilm formers and 9 (52.9%) were categorized as weak biofilm formers. Only 5 isolates (29.4%) were non-biofilm formers. 50% citrus honey concentration was defined as minimum inhibitory concentration (MIC) for 3 isolates, and a concentration of 12.5% was defined as MIC for 1 isolate. Our study showed high AR rates toward the used antibiotics, besides the ESBL production and biofilm formation ability. Egyptian citrus honey at a concentration of 50% and 12.5% had the ability to inhibit 23.53% of E.coli isolates, having antibacterial potency against those AR pathogenic strains.
Cite this article:
Sara H. Mohamed, Maram M. S. Elshahed, Yasmine M. Saied. Evaluation of Honey as an Antibacterial Agent against Drug-Resistant Uropathogenic E. coli strains. Research J. Pharm. and Tech. 2020; 13(8):3720-3724. doi: 10.5958/0974-360X.2020.00658.7
Cite(Electronic):
Sara H. Mohamed, Maram M. S. Elshahed, Yasmine M. Saied. Evaluation of Honey as an Antibacterial Agent against Drug-Resistant Uropathogenic E. coli strains. Research J. Pharm. and Tech. 2020; 13(8):3720-3724. doi: 10.5958/0974-360X.2020.00658.7 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-8-31
REFERENCES:
1. Mohamed SH, Khalil MS, Mohamed MSM, Mabrouk MI. Prevalence of antibiotic resistance and biofilm formation in Klebsiella pneumoniae carrying fimbrial genes in Egypt. Res J Pharm Technol. 2020.
2. Mohamed M, Mostafa H, Mohamed S, El-Moez SA, Kamel Z. Combination of Silver Nanoparticles and Vancomycinto Overcome Antibiotic Resistance in Planktonic/Biofilm Cell from Clinical and Animal Source. Microb DRUG Resist. 2020. doi:10.1089/mdr.2020.0089.
3. Raeispour M, Ranjbar R. Antibiotic resistance, virulence factors and genotyping of Uropathogenic Escherichia coli strains. Antimicrob Resist Infect Control. 2018; 7:118.
4. Mohamed MSM, Abdallah AA, Mahran MH, Shalaby M. Potential Alternative Treatment of Ocular Bacterial Infections by Oil Derived from Syzygium aromaticum Flower (Clove). Curr Eye Res. 2018;43(7):873-881. doi:10.1080/02713683.2018.1461907.
5. Delpech G, Allende NG, Lissarrague S, Sparo M. Antimicrobial Resistance of Uropathogenic Escherichia coli from Elderly Patients at a General Hospital, Argentina. Open Infect Dis J. 2018;10: 79-87. doi:10.2174/1874279301810010079.
6. Baby S, Karnaker VK, Geetha RK. Adhesins of Uropathogenic Escherichia coli (UPEC). Int J Med Microbiol Trop Dis. 2016;2(1):10-18.
7. Adamus-białek W, Kubiak A, Czerwonka G. Analysis of uropathogenic Escherichia coli biofilm formation under different growth conditions. Acta Biochim Pol. 2015;62(4):765-771.
8. Gawad WE, Helmy OM, Tawakkol WM, Hashem AM. Antimicrobial Resistance, Biofilm Formation, and Phylogenetic Grouping of Uropathogenic Escherichia coli Isolates in Egypt: The Role of Efflux Pump-Mediated Resistance. Jundishapur J Microbiol. 2018;11(2):e14444. doi: 10.5812/jjm.14444.Research.
9. Karigoudar RM, Karigoudar MH, Wavare SM, Mangalgi SS. Detection of biofilm among uropathogenic Escherichia coli and its correlation with antibiotic resistance pattern. J Lab Physicians. 2019;11(2):17-22. doi: 10.4103/JLP.JLP.
10. Mohamed SH, Khalil MS, Azmy M. In vitro Efficiency of Ampicillin, Thymol and Their Combinations against Virulence Strains of Klebsiella pneumoniae. Int J Pharm Res. 2019;11(3):315-321.
11. Abbas HA, El-Sayed MA, Kamel MM, Gamil L. Allium kurrat and Eruca sativa are Natural agents for Inhibition and Eradication of Enterohemorrhagic Escherichia coli O157:H7 Biofilm. Res J Pharm Technol. 2014;7(4):425-428.
12. Chauhan A, Pandey V, Chacko KM, Khandal RK. Antibacterial Activity of Raw and Processed Honey. Electron J Biol. 2010;5(3):58-66.
13. Almasaudi SB, Al-nahari AAM, Sayed E, et al. Antimicrobial effect of different types of honey on Staphylococcus aureus. Saudi J Biol Sci. 2017;24(6):1255-1261. doi:10.1016/j.sjbs.2016.08.007.
14. Auguskani JPL. A study to assess the chemical composition and antibacterial properties of honey. Biomed Res. 2018;29(19):3584-3589.
15. Nairoukh YR, Mahafzah AM, Irshaid A, Shehabi AA. Molecular Characterization of Multidrug Resistant Uropathogenic E. coli Isolates from Jordanian Patients. Open Microbiol J. 2018;12:1-7. doi:10.2174/1874285801812010001.
16. CLSI. M100, 29th Performance Standards for Antimicrobial Susceptibility Testing.; 2019.
17. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Vol 32.; 2012. doi:10.1038/nprot.2008.226.
18. Mohamed SH, Salem D, Azmy M, Fam NS. Antibacterial and antibiofilm activity of cinnamaldehyde against carbapenem-resistant Acinetobacter baumannii in Egypt: In vitro study. J Appl Pharm Sci. 2018;8(11):151-156. doi:10.7324/JAPS.2018.81121.
19. Mama M, Teshome T, Detamo J. Antibacterial Activity of Honey against Methicillin-Resistant Staphylococcus aureus: A Laboratory-Based Experimental Study. Int J Microbiol. 2019; 2019:7686130. doi:10.1155/2019/7686130.
20. Bien J, Sokolova O, Bozko P. Role of Uropathogenic Escherichia coli Virulence Factors in Development of Urinary Tract Infection and Kidney Damage. Int J of Nephrology. 2012; 2012:681473. doi:10.1155/2012/681473.
21. Habibi A, Khameneie MK. Antibiotic resistance properties of uropathogenic Escherichia coli isolated from pregnant women with history of recurrent urinary tract infections. Trop J Pharm Res. 2016;15(8):1745-1750.
22. Romaihi E Al, Safaa M, Khawaja A, et al. Prevalence of Antimicrobial Resistance in Uropathogens among Patients Visiting Primary Health Centers: Implications for Empiric Therapy. Bahrain Med Bull. 2018;40(4):207-211.
23. Lawhale MA, Naikwade R. Recent pattern of drug sensitivity of most commonly isolated uropathogens from Central India. Int J Res Med Sci. 2017;5(8):3631-3636.
24. Oluwafemi TT, Akinbodewa AA, Ogunleye A, Ademola O. Urinary tract infections and antibiotic sensitivity pattern of uropathogens in a tertiary hospital in South West, Nigeria. Sahel Med J. 2018; 21:18-22. doi:10.4103/1118-8561.232779.
25. Bitew A, Molalign T, Chanie M. Species distribution and antibiotic susceptibility profile of bacterial uropathogens among patients complaining urinary tract infections. BMC Infect Dis. 2017;17:654. doi:10.1186/s12879-017-2743-8.
26. Ahmed SS, Shariq A, Alsalloom AA, Babikir IH, Alhomoud BN. Uropathogens and their antimicrobial resistance patterns: Relationship with urinary tract infections. Int J Health Sci (Qassim). 2019;13(2):48-55.
27. Alamri A, Hamid ME, Abid M, et al. Trend analysis of bacterial uropathogens and their susceptibility pattern: A 4‑year (2013-2016) study from Aseer region, Saudi Arabia. Urol Ann. 2018;10:41-46. doi:10.4103/UA.UA.
28. Anima N, Dhamodharan S, Nayak B. Antibiotic Resistance Pattern Exhibited by ESBL (Extended Spectrum β-Lactamases) in Multidrug Resistant Strains, Escherichia coli. Res J Pharm Technol. 2017;10(11):3705.
29. Sagar S, Gopinath P. Detection of bla CTX-M gene for ESBL Production Among Clinical Isolates of Escherichia coli. Res J Pharm Technol. 2016;9(10):1593.
30. Sanmugam K, Gopinath P. Detection of blaSHV-1 for ESBL production among clinical strains of Escherichia coli. Res J Pharm Technol. 2016;9(9):1447-1450.
31. Baaity Z, Almahmoud I, Khamis A. Prevalence of Extended Spectrum β Lactamases (ESBL) in E. coli at Al-Assad Teaching Hospital. Res J Pharm Technol. 2017;10(7):2433-2436.
32. Mary RNI, Banu N. Inhibition of biofilm formation in Serratia marcescens by Andrographolide from Andrographis paniculata. Res J Pharm Technol. 2017;10(3):789-791.
33. Mohamed SH, Mohamed MSM, Khalil MS, Azmy M, Mabrouk MI. Combination of essential oil and ciprofloxacin to inhibit/eradicate biofilms in multidrug-resistant Klebsiella pneumoniae. J Appl Microbiol. 2018; 125:84-95. doi:10.1111/jam.13755.
34. Deepigaa M. Antibacterial Resistance of Bacteria in Biofilms. Res J Pharm Technol. 2017;10(11):4019-4023.
35. Mohamed SH, Mohamed MSM, Khalil MS, Mohamed WS, Mabrouk MI. Antibiofilm activity of papain enzyme against pathogenic Klebsiella pneumoniae. J Appl Pharm Sci. 2018;8(06):163-168. doi:10.7324/JAPS.2018.8621.
36. Albaridi NA. Antibacterial Potency of Honey. Int J Microbiol. 2019;2019:2464507.
37. Abbas HA. Antibacterial, Anti-swarming and Antibiofilm Activities of Local Egyptian Clover Honey Against Proteus Mirabilis Isolated from Diabetic Foot Infection. Asian J Pharm Res. 2013;3(3):114-117.
38. Zam W, Harfouch R, Bittar S, Sayegh M. Antibacterial activity of various Syrian honey types against Pseudomonas aeruginosa. Res J Pharmacogn Phytochem. 2017;9(2):73-76.
39. Zam W, Harfouch R, Mais AD, Rand K. Anti-Staphylococcus aureus efficacy of six natural honey samples originated from Syria. Res J Pharmacogn Phytochem. 2018;10(1):23-26.
40. Sam JA, Gopinath P. Antibacterial Activity of Honey Against Clinical Isolates of Pseudomonas aeruginosa. Res J Pharm Technol. 2016;9(8):1174-1176.
41. Mandal MD, Mandal S. Honey: its medicinal property and antibacterial activity. Asian Pac J Trop Biomed. 2011;1(2):154-160. doi:10.1016/S2221-1691(11)60016-6.
42. Wilkinson J, Cavanagh HMA. Antibacterial Activity of 13 Honeys Against Escherichia coli and Pseudomonas aeruginosa. J Med Food. 2005;8(1):100-103. doi:10.1089/jmf.2005.8.100.